Navigation Links
Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D'
Date:3/26/2009

Industry publication R&D Directions honors Dr. Sellers' pioneering work in human abuse liability studies

CINCINNATI, March 26 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Edward Sellers, MD, PhD, Senior Scientist and General Manager of the company's Early Stage Unit in Toronto, has been named one of nine "Notable People in R&D" by leading industry publication R&D Directions. Dr. Sellers, one of only two honorees from the CRO industry to make the 2009 list, was selected based on his pioneering efforts in human abuse liability studies, assessment of abuse potential, risk mitigation, the measurement of pharmacodynamic effects of CNS drugs, pharmacogenetics and alcohol interactions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"We are pleased to have the top expert in human abuse liability assessment as part of the Kendle organization," said Simon Higginbotham, President. "With more than three decades of experience in Early Stage research, Ed is a proven leader in the Early Stage arena." He continued, "Early Stage continues to be an area of focus for Kendle, from First-in-Human studies through Phase IIa/proof-of-concept. We will continue to expand our capabilities and look forward to the ongoing contributions of Ed and our Toronto team."

Under Dr. Sellers' direction, the Kendle team in Toronto has amassed more experience in abuse liability assessments than any institution in the world and remains the only CRO conducting these studies. The unit is recognized internationally by global regulatory authorities, and has the world's largest database of recreational drug users, ensuring that subjects can be enrolled rapidly and efficiently into these critical studies. Today, the 86-bed inpatient unit is an integral part of Kendle's overall early stage services.

"I'm honored to have been chosen for this prestigious recognition," said Dr. Sellers. "I believe it is a reflection of the groundbreaking work done by my world-class team." He continued, "The abuse of prescription drugs has become a serious concern for healthcare providers, drug manufacturers and governmental regulators. Our team provides regulatory agencies and manufacturers with a scientific basis on which to schedule drugs and helps prevent the devastating effects of addiction. It is extremely rewarding to know that our team is helping the biopharmaceutical industry combat this problem."

Dr. Sellers joined Kendle in 2008 as part of the acquisition of DecisionLine Research Corporation, which he co-founded in 1997 and for which he served as President and CEO. He oversees day-to-day operations of Kendle's Early Stage Unit in Toronto as well as all scientific research conducted at the facility.

The R&D Directions editorial staff selected the 2009 "Notable People in R&D" from industry-submitted nominations based on the innovative nature of each nominee's work. The selection of Dr. Sellers marks the second time the publication has named a Kendle expert to their "Notable" list. In 2007, William Sietsema, PhD, Vice President, U.S. Regulatory Consulting and Submissions, was chosen based on his work in innovative trial design.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest- growing companies in the United States for 2008. The company also has been recognized as the "Top CRO to Work With" in the CenterWatch 2007 survey of U.S. investigative sites and among the "Top CROs in Europe" in the 2008 survey of European sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LEXINGTON, Massachusetts , February 4, 2016 - New ... --> - New FDA action date of July ... date of July 22, 2016   - ... the U.S. in the past decade indicated for the treatment of signs and ... Lifitegrast has the potential to be the only product approved in the ...
(Date:2/4/2016)... 4, 2016  CytoSorbents Corporation (NASDAQ: CTSO ... flagship CytoSorb® blood filter to treat deadly inflammation ... world, announced that CEO Dr. Phillip Chan ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... Conference Presentation Details: Where: Convene ...
(Date:2/4/2016)... Feb. 4, 2016 Sinovac Biotech Ltd. ("Sinovac" ... provider of biopharmaceutical products in China ... board of directors received on February 4, 2016 a ... a consortium comprised of PKU V-Ming ( Shanghai ... Ltd., CICC Qianhai Development ( Shenzhen ) ...
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
Breaking Biology News(10 mins):